20230109 lab meeting_怡君 (no sound)
-
00:00
1.
index 1
-
00:28
2.
Slide 2
-
00:29
3.
HBV-related hepatocellular carcinoma
-
02:15
4.
HBV induces protein O-GlcNAcylation in liver cancer
-
03:29
5.
Hexosamine Biosynthetic Pathway (O-GlcNAcylation)
-
05:00
6.
RNA N6-methyladenosine (m6A) Modification
-
06:18
7.
Slide 7
-
06:42
8.
Slide 8
-
07:47
9.
HBV infection enhanced YTHDF2 O-GlcNAcylation in vivo and clinical
-
07:50
10.
Slide 8
-
07:58
11.
HBV infection enhanced YTHDF2 O-GlcNAcylation in vivo and clinical
-
10:31
12.
HBV infection enhanced YTHDF2 O-GlcNAcylation in vitro
-
12:58
13.
OGT interacted with the N-terminal region of YTHDF2
-
23:00
14.
Ser263 is the major O-GlcNAcylation site of YTHDF2
-
29:00
15.
YTHDF2 protein was more stable after HBV infection in HCCKnockdown of OGT greatly shortened YTHDF2 lifespan
-
34:57
16.
TMG treatment could not restorereducing YTHDF2 half-life by S263A- YTHDF2 mutant
-
35:39
17.
Slide 15
-
35:40
18.
TMG treatment could not restorereducing YTHDF2 half-life by S263A- YTHDF2 mutant
-
38:36
19.
Slide 15
-
47:39
20.
O-GlcNAcylation of YTHDF2 promotes hepatocellular carcinoma cell proliferation, invasion and migration in vitro
-
49:57
21.
O-GlcNAcylation of YTHDF2 promotes tumor growth in vivo
-
50:37
22.
Identification of YTHDF2 targets by RNA-seq, m6A-seq and RIP-seq
-
58:19
23.
O-GlcNAcylation of YTHDF2 increased MCM2/5 mRNA stability in an m6A-dependent manner
-
1:06:02
24.
MCM2/5 promotes HCC proliferation by O-GlcNAcylation of YTHDF2
-
1:08:24
25.
Slide 21
-
1:10:38
26.
Slide 22
-
1:11:46
27.
Slide 23
-
1:12:37
28.
Slide 24
-
1:12:38
29.
Conclusion
-
1:13:33
30.
Comments
-
1:13:37
31.
Conclusion
-
1:14:02
32.
Comments
-
1:14:42
33.
Slide 27
-
1:15:11
34.
** after 20231030 meeting.pptx
-
00:00
1.
index 1
-
00:28
2.
Slide 2
-
00:29
3.
HBV-related hepatocellular carcinoma
-
02:15
4.
HBV induces protein O-GlcNAcylation in liver cancer
-
03:29
5.
Hexosamine Biosynthetic Pathway (O-GlcNAcylation)
-
05:00
6.
RNA N6-methyladenosine (m6A) Modification
-
06:18
7.
Slide 7
-
06:42
8.
Slide 8
-
07:47
9.
HBV infection enhanced YTHDF2 O-GlcNAcylation in vivo and clinical
-
07:50
10.
Slide 8
-
07:58
11.
HBV infection enhanced YTHDF2 O-GlcNAcylation in vivo and clinical
-
10:31
12.
HBV infection enhanced YTHDF2 O-GlcNAcylation in vitro
-
12:58
13.
OGT interacted with the N-terminal region of YTHDF2
-
23:00
14.
Ser263 is the major O-GlcNAcylation site of YTHDF2
-
29:00
15.
YTHDF2 protein was more stable after HBV infection in HCCKnockdown of OGT greatly shortened YTHDF2 lifespan
-
34:57
16.
TMG treatment could not restorereducing YTHDF2 half-life by S263A- YTHDF2 mutant
-
35:39
17.
Slide 15
-
35:40
18.
TMG treatment could not restorereducing YTHDF2 half-life by S263A- YTHDF2 mutant
-
38:36
19.
Slide 15
-
47:39
20.
O-GlcNAcylation of YTHDF2 promotes hepatocellular carcinoma cell proliferation, invasion and migration in vitro
-
49:57
21.
O-GlcNAcylation of YTHDF2 promotes tumor growth in vivo
-
50:37
22.
Identification of YTHDF2 targets by RNA-seq, m6A-seq and RIP-seq
-
58:19
23.
O-GlcNAcylation of YTHDF2 increased MCM2/5 mRNA stability in an m6A-dependent manner
-
1:06:02
24.
MCM2/5 promotes HCC proliferation by O-GlcNAcylation of YTHDF2
-
1:08:24
25.
Slide 21
-
1:10:38
26.
Slide 22
-
1:11:46
27.
Slide 23
-
1:12:37
28.
Slide 24
-
1:12:38
29.
Conclusion
-
1:13:33
30.
Comments
-
1:13:37
31.
Conclusion
-
1:14:02
32.
Comments
-
1:14:42
33.
Slide 27
-
1:15:11
34.
** after 20231030 meeting.pptx
- 位置
-
- 資料夾名稱
- 2023
- 發表人
- 周楷軒
- 單位
- 賴亮全教授
- 建立
- 2023-10-30 10:47:27
- 最近修訂
- 2023-10-30 11:17:48
- 長度
- 1:15:17
